AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01729845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT01729845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT01729845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01729845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01729845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study NCT00890890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avagacestat
Description: Capsules, Oral, 50 mg, once daily, 104 - 220 Weeks
Study NCT00890890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 104 - 220 Weeks
Study NCT02460055 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endotracheal tube
Description: This study will determine if the placement of an ETT will lead to dysphagia.
Study NCT02460055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol 3mg/kg will be administered to facilitate endotracheal intubation
Study NCT02460055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation
Study NCT02460055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 0.15mg/kg up to 20 mg will be used for anti-emesis prophylaxis
Study NCT02460055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron 0.15mg/kg up to 4mg will be used for anti-emesis prophylaxis
Study NCT02460055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane, nitrous oxide and oxygen
Description: Inhalational agents will be used to induce general anesthesia
Study NCT04565262 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NAs+IFN-α
Description: NAs+IFN-α:(NAs +IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96 weeks。 NAs+(NAs+IFN-α) :NAs/48weeks+(NAs+ IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）for 48 weeks ，then combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96weeks。 Response guided treatment（RGT） by HBsAg quantification： The course of interferon alpha was 24 weeks after HBsAg and HBeAg turned negative up to 96 weeks, and NAs was discontinued 12 months after HBsAg serological conversion.
Study NCT04565262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAs+IFN-α
Description: NAs+IFN-α:(NAs +IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96 weeks。 NAs+(NAs+IFN-α) :NAs/48weeks+(NAs+ IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）for 48 weeks ，then combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96weeks。 Response guided treatment（RGT） by HBsAg quantification： The course of interferon alpha was 24 weeks after HBsAg and HBeAg turned negative up to 96 weeks, and NAs was discontinued 12 months after HBsAg serological conversion.
Study NCT02080546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cut-Coag
Description: Incision using electrothermal cautery, with an attempt made to use the cut (continuous low-voltage, high-current) for colpotomy incision following the initial scoring of the cervico-vaginal tissue on the coag (pulsed high-voltage, low-current) mode.
Study NCT02080546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: V-mode
Description: Incision using electrothermal cautery in the V mode. The V mode combines real-time tissue sensing technology with the cut and coag waveforms to reduce the amount of thermal spread to the tissue without sacrificing hemostasis during monopolar electrothermal procedures.
Study NCT02080546 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Valleylab G3000 Electrosurgical Device
Description: Use of surgical device Valleylab G3000 Electrosurgical Device
Study NCT02080546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valleylab G3000 Electrosurgical Device
Description: Use of surgical device Valleylab G3000 Electrosurgical Device
Study NCT00104767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Study NCT00844597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-4658 for Injection
Description: AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.
Study NCT01931982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Victoza
Study NCT00550212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272, Single-dose capsule and solution
Study NCT02392104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.
Study NCT02581059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.
Study NCT02581059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.
Study NCT02581059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginseng
Description: Subjects randomized to ginseng will receive 1,000 mg orally twice every day of each 28-day cycle for 2 cycles.
Study NCT01299311 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NEAT
Description: 4 days of everyday activities, including 4 hours of walking, 8 hours of sitting, 2 hours of standing, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
Study NCT01299311 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 4 days of activity program, including 1 hour biking (exercise), 13 hours of sitting, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
Study NCT01963169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TO-BoneHealth Program (Bone Power Program)
Description: The 8-week TO-BoneHealth program include: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
Study NCT01963169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TO-BoneHealth Plus Program (Bone Power Plus Program)
Description: This intervention includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
Study NCT00665093 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
Study NCT00665093 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
Study NCT01183247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Add rapamycin de novo to tacrolimus and MMF
Study NCT01183247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Add everolimus de novo to tacrolimus and MMF
Study NCT01183247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Add prednisone de novo to tacrolimus and MMF
Study NCT01262092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
Study NCT01262092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buprenorphine
Description: Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
Study NCT04182347 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health Research ToolKit Development
Description: The Toolkit will be an accessible, structured process for people with IDD and people with IDD's paid and unpaid caregivers to be engaged partners. Learning activities are focused on leadership, information about research, health for individuals with IDD. Learning activities will include topics:~What is health research? What is the health research process? How can individuals with IDD be involved in health research? Where is research happening? How to think like a researcher. Creating health stories for research and care advocacy.~The learning activities will teach individuals with IDD information and allow participants to practice the learning.
Study NCT01386723 — intervention group
Intervention type: DRUG
Intervention: Discontinuation of eltrombopag
Description: Observation of subjects as they discontinue the use of eltrombopag
Study NCT02994771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lymfactin® [1 x 10E10 vp]
Description: Lymfactin® \[1 x 10E10 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.
Study NCT02994771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lymfactin® [1 x 10E11 vp]
Description: Lymfactin® \[1 x 10E11 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.
Study NCT04565002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Diaphragmatic Stimulation
Description: The procedure consists of electrical stimulation in the region of the motor points of the diaphragm. Its configurations contribute to produce involuntary muscle contractions. There are four electrodes positioned superficially on the skin.
Study NCT03506347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Antibiotic
Study NCT03506347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Antibiotic
Study NCT01554722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle placement
Description: In plane versus out of plane needle placement techniques
Study NCT00794170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone and Print based intervention
Description: Thiss intervention consisted of tailored phone calls and follow-up mailings.
Study NCT01030718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID
Study NCT01474629 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic-based dietary supplement
Description: 24 trained men receive a probiotic-based dietary supplement for 16 weeks. Dosage 3x 10-9 per day
Study NCT01474629 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 24 trained men receive a placebo for 16 weeks with same dosage compared to active group
Study NCT03214536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block
Description: bilateral injection of local anaesthetic between the erector spinae muscle and the transverse process
Study NCT03214536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: injection of 20 ml ropivacaine 0.375 % bilateral by erector spinae block
Study NCT03214536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spine surgery
Description: Surgery of lumbar spine
Study NCT03214536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anesthesia
Description: general anesthesia
Study NCT01249508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition label
Study NCT01294059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: 50 mg BID Oral x 6 Weeks
Study NCT01294059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Milnacipran
Description: 50 mg BID Oral x 6 Weeks
Study NCT00099632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate
Description: 200mg/300mg as one tablet taken orally once daily
Study NCT00099632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/Zidovudine
Description: 150mg/300mg as one tablet taken orally twice daily
Study NCT02772237 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin 400mg daily
Study NCT02772237 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01937026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT01937026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Administered orally
Study NCT02984254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Womac
Description: Answer Womac questionnaires at baseline, 1 month, 3 months and 1 year
Study NCT02984254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lequesne
Description: Answer Lequesne questionnaires at baseline, 1 month, 3 months and 1 year
Study NCT02984254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Timed-up-and-go (TUG)
Description: Perform Timed-up-and-go (TUG) at baseline, 1 month, 3 months and 1 year
Study NCT02984254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: five-times-sit-to-stand-test (FTSST)
Description: Perform the five-times-sit-to-stand-test (FTSST) at baseline, 1 month, 3 months and 1 year
Study NCT00099632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: 133.3mg/33.3mg as three capsules taken orally twice daily
Study NCT00099632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose Nevirapine
Description: one 200 mg tablet taken orally
Study NCT03240185 — intervention group
Intervention type: BEHAVIORAL
Intervention: deep breathing exercises
Description: Patients receive education on deep breathing exercises for pain control as part of their pre-operative appointment
Study NCT03236116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almonds
Description: Participants will consume almonds everyday for 6 months.
Study NCT03236116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (no nuts)
Description: Participants will not be permited to consume any nuts for 6 months.
Study NCT01638195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: Focused Ultrasound
Study NCT03811054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib（250mg/d） combined with EGFR-TKI
Description: Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
Study NCT02984254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Six-minute walk test.
Description: Perform six-minute walk test at baseline, 3 months and 1 year
Study NCT02984254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional patellofemoral neoprene brace
Description: Use the functional patellofemoral neoprene brace for 2 hours/day minimum - 12 hours/day maximum
Study NCT02984254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neoprene sleeve brace.
Description: Use the neoprene sleeve brace for 2 hours/day minimum - 12 hours/day maximum
Study NCT01675349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prick test Chenopodium album allergen extract
Description: This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Chenopodium album allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
Study NCT04881279 — intervention group
Intervention type: OTHER
Intervention: Event
Description: Ransomware attack
Study NCT03648528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Study NCT03648528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00460902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Study NCT00975676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gas chromatography / tandem mass spectometry
Description: Determination of estrogen levels through gas chromatography.
Study NCT02538315 — intervention group
Intervention type: DRUG
Intervention: [18F]FDOPA PET/CT
Description: Implantation of fetal dopaminergic stem cell transplantation by neuro-surgeon followed by \[18F\]FDOPA PET/CT imaging
Study NCT02548078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
Description: A single dose administered intramuscular
Study NCT02548078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine
Description: A single dose administered intramuscular
Study NCT02242643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluLaval™ Quadrivalent
Description: 1 or 2 doses administered intramusculary (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
Study NCT02242643 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® Quadrivalent
Description: 1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
Study NCT00611169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirofiban
Description: tirofiban (25 μg/kg bolus and 0.15 μg/kg/min maintenance infusion for 24 hours)
Study NCT00372853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
Study NCT00372853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: SU011248 administered at a dose of 37.5mg/day every day.
Study NCT00372853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.
Study NCT03210649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519
Description: Part 1 : CKD-519(100mg x 4 Tablets) for D1 Part 2 : CKD-519(100mg x 4 Tablets) for D1\~D14
Study NCT03210649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Part 1 : CKD-519 placebo(100mg x 4 Tablets) for D1 Part 2 : CKD-519 placebo(100mg x 4 Tablets) for D1\~D14
Study NCT03228147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation
Description: Given PO
Study NCT03228147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04058002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiprofessional treatment and Educational Program Associated (EPA+C+BCAA) with supplementation of creatine and BCAA.
Description: 17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of BCAA (1,200 milligrams of leucine, 600 milligrams of isoleucine and 600 milligrams of valine per dose)